• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series.

作者信息

Weng H-J, Wang T-S, Tsai T-F

机构信息

Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan.

Department of Dermatology, Chung Shan Medical University, Taichung, Taiwan.

出版信息

Br J Dermatol. 2018 Jun;178(6):1439-1440. doi: 10.1111/bjd.16252. Epub 2018 Mar 23.

DOI:10.1111/bjd.16252
PMID:29265175
Abstract
摘要

相似文献

1
Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series.司库奇尤单抗治疗红皮病型银屑病的临床经验：病例系列
Br J Dermatol. 2018 Jun;178(6):1439-1440. doi: 10.1111/bjd.16252. Epub 2018 Mar 23.
2
Erythrodermic psoriasis and secukinumab: Our clinical experience.红皮病型银屑病与司库奇尤单抗：我们的临床经验
Dermatol Ther. 2018 Jul;31(4):e12607. doi: 10.1111/dth.12607. Epub 2018 Apr 16.
3
Long-term remission induced by secukinumab in a 13-year-old boy having recalcitrant chronic erythrodermic psoriasis.司库奇尤单抗诱导一名13岁顽固性慢性红皮病型银屑病男孩实现长期缓解。
Dermatol Ther. 2018 Jul;31(4):e12611. doi: 10.1111/dth.12611. Epub 2018 Apr 23.
4
Secukinumab for the treatment of residual psoriasis: a case series.司库奇尤单抗治疗残留银屑病：病例系列
J Dermatolog Treat. 2018;29(sup1):12-13. doi: 10.1080/09546634.2018.1524819.
5
Secukinumab for plaque psoriasis with ocular comorbidity: a clinical experience.用于治疗合并眼部疾病的斑块状银屑病的司库奇尤单抗：临床经验
J Dermatolog Treat. 2018;29(sup1):9-11. doi: 10.1080/09546634.2018.1527995.
6
Clinical experience of ixekizumab in the treatment of patients with history of chronic erythrodermic psoriasis who failed secukinumab: a case series.司库奇尤单抗治疗失败的慢性红皮病型银屑病病史患者使用依奇珠单抗的临床经验：病例系列
Br J Dermatol. 2019 Nov;181(5):1106-1107. doi: 10.1111/bjd.18174. Epub 2019 Aug 20.
7
From biologic to biologic to biologic: lessons to learn for erythrodermic and recalcitrant chronic plaque psoriasis.从生物制剂到生物制剂再到生物制剂：红皮病型和顽固性慢性斑块状银屑病的经验教训
Australas J Dermatol. 2008 Aug;49(3):152-5. doi: 10.1111/j.1440-0960.2008.00463.x.
8
Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis.英夫利昔单抗作为单一疗法或联合疗法，可促使红皮病型银屑病迅速消退。
Br J Dermatol. 2007 Oct;157(4):828-31. doi: 10.1111/j.1365-2133.2007.08111.x. Epub 2007 Aug 17.
9
Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis.英夫利昔单抗联合甲氨蝶呤用于红皮病型银屑病的长期治疗。
Arch Dermatol. 2005 Dec;141(12):1607-10. doi: 10.1001/archderm.141.12.1607.
10
Secukinumab reduces plasma oxidative stress in psoriasis: A case-based experience.
Dermatol Ther. 2018 Sep;31(5):e12675. doi: 10.1111/dth.12675. Epub 2018 Aug 22.

引用本文的文献

1
Management of Erythrodermic Psoriasis with Systemic Therapies: A Systematic Review.全身性疗法治疗红皮病型银屑病的系统评价
Am J Clin Dermatol. 2025 Aug 26. doi: 10.1007/s40257-025-00977-1.
2
Efficacy and Safety of Adalimumab and Secukinumab in Erythrodermic Psoriasis: A Single Centre Retrospective Study.阿达木单抗和司库奇尤单抗治疗红皮病型银屑病的疗效与安全性：一项单中心回顾性研究
Indian J Dermatol. 2025 Jul-Aug;70(4):221. doi: 10.4103/ijd.ijd_1051_23. Epub 2025 Jun 30.
3
Update on Erythrodermic Psoriasis: Proposal of a Management Algorithm by an Innovative Severity Evaluation Approach.
红皮病型银屑病的最新进展：通过创新的严重程度评估方法提出管理算法建议。
Psoriasis (Auckl). 2025 Jul 19;15:301-320. doi: 10.2147/PTT.S532062. eCollection 2025.
4
Biologic anti-IL17 drugs in erythrodermic psoriasis.用于红皮病型银屑病的生物抗白细胞介素-17药物。
JAAD Int. 2024 Jun 22;16:257-263. doi: 10.1016/j.jdin.2024.05.007. eCollection 2024 Sep.
5
Comparison of Drug-Free Remission after the End of Phase III Trials of Three Different Anti-IL-23 Inhibitors in Psoriasis.三种不同抗白细胞介素-23抑制剂治疗银屑病III期试验结束后无药缓解情况的比较
Dermatol Ther (Heidelb). 2024 Sep;14(9):2607-2620. doi: 10.1007/s13555-024-01229-6. Epub 2024 Jul 29.
6
Biologics for the Management of Erythrodermic Psoriasis: An Updated Review.用于红皮病型银屑病治疗的生物制剂：最新综述
Clin Cosmet Investig Dermatol. 2023 Aug 4;16:2045-2059. doi: 10.2147/CCID.S407813. eCollection 2023.
7
Biologics and Biosimilars in Psoriasis.银屑病中的生物制剂和生物类似药
Indian J Dermatol. 2023 May-Jun;68(3):282-295. doi: 10.4103/ijd.ijd_421_23.
8
Association between IL-17F, IL-17RA Gene Polymorphisms and Response to Biological Drugs in Psoriasis and Beyond.白细胞介素 17F、白细胞介素 17RA 基因多态性与银屑病及其他疾病生物药物反应的相关性。
Genes (Basel). 2023 May 22;14(5):1123. doi: 10.3390/genes14051123.
9
The Inflammatory Factor SNP May Serve as a Promising Biomarker for Acitretin to Alleviate Secondary Failure of Response to TNF-a Monoclonal Antibodies in Psoriasis.炎症因子单核苷酸多态性可能是阿维A减轻银屑病中对肿瘤坏死因子-α单克隆抗体继发反应失败的一个有前景的生物标志物。
Front Pharmacol. 2022 Jun 24;13:937490. doi: 10.3389/fphar.2022.937490. eCollection 2022.
10
Erythrodermic psoriasis and palmoplantar hyperkeratosis successfully treated with secukinumab: a case report.司库奇尤单抗成功治疗红皮病型银屑病和掌跖角化过度：一例报告
Drug Target Insights. 2022 Mar 7;16:1-5. doi: 10.33393/dti.2022.2355. eCollection 2022 Jan-Dec.